期刊文献+

房颤患者规范化抗凝治疗现状调研 被引量:6

Study of Standardized Anticoagulant Therapy in Patient with Atrial Fibrillation
下载PDF
导出
摘要 目的:了解心房颤动患者规范化抗凝治疗现状,分析影响规范化抗凝治疗的因素,同时为进一步提出相应的对策打下基础。方法:查阅2010年1~12月份南京鼓楼医院心内科明确诊断患有非瓣膜性心房颤动的患者病历,采用CHADS2风险评分法对这些患者进行出血风险评估,根据ACC/AHA/ESC心房颤动治疗指南评价其规范化抗凝情况。结果:共入选患者200名,使用华法林进行抗凝治疗的仅39人(19.5%),其中仅有18人(46%)国际标准化比值(INR)达目标抗凝范围(INR:2.0~3.0);按照CHADS2评分将入组患者分组,其中高危患者143人中,进行华法林抗凝治疗的仅31人。结论:心房颤动患者进行规范抗凝治疗的比例很低(40%),其中高危患者中使用华法林进行规范治疗的比例尤甚(22%)。由此,应针对房颤患者规范化抗凝治疗率低的现状,进一步调查与了解发生这一现象的原因,从而采取有效的干预措施,提高房颤患者规范化抗凝治疗率。 Objective: To understand current the state of standardized anticoagulant therapy in patient with atrial fibrillation and analyze the factors that affect standard anticoagulant therapy,and at the same time,to make progress by the foundation of corresponding countermeasures.Methods:Diagnosed non-valvular atrial fibrillation patients were history inspected for a period of 12 months(January-December 2010) in Nanjing Drum Tower Hospital Cardiovascular Department,CHADS2 scheme method was used to stratify atrial fibrillation patient and assess their risk of bleeding,the standardized anticoagulant therapy conditions were evaluated according to ACC/AHA/ESC(American College of Cardiology/American Heart Association/ European Society of Cardiology) atrial fibrillation treatment guidelines.Results: A total of 200 patients were enrolled,39(19.5%) patient were on warfarin anticoagulant therapy,among which 18(46%) had international normalized ratio(INR) in therapeutic range(2.0~3.0).According to the CHADS2 scheme,143 patients were divided into the high risk group,in which only 31 were on warfarin anticoagulant treatment.Conclusion: The percentage of standard anticoagulant treatment in patients with atrial fibrillation is very low(40%),still more,the percentage of high risk patients using warfarin standard anticoagulant treatment was even low 22%.Further investigation and understanding of the causes of this phenomenon will help intervene effectively and improve the standard of anticoagulant therapy in patient with atrial fibrillation.
出处 《药学与临床研究》 2011年第4期348-351,共4页 Pharmaceutical and Clinical Research
关键词 心房颤动 华法林 规范化抗凝治疗 CHADS2风险评分 Atrial Fibrillation Warfarin Standardization Anticoagulant Therapy CHADS2 Risk Score
  • 相关文献

参考文献19

  • 1Lip GY, Godtfredsen J. Cardiac arrhythmias: a clinical approach[M]. Edinburgh, UK: Mosby, 2003: 3- 24.
  • 2Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis [J]. Ann Intern Med, 1999, 131(7): 492 501.
  • 3Lane D, Lip GY. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment[J]. Age Ageing, 2005, 34(1): 1-3.
  • 4Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation [J].J Am Med Assoc, 285(22): 2864-70.
  • 5Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism [J]. Patient Prefer Adherence, 2010, 4: 51-60.
  • 6Coll-Vinent B. Anticoagulant in atrial fibrillation: a changing concept[J]. Emergenclas, 2009, 21: 403-4.
  • 7Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrhematic atrial fibrillation[J]. J Gen Intern Med, 1996, 11(12): 713-20.
  • 8Chang H J, Bell JR,Deroo BD, et al. Physician variation in anticoagulant patient with atrial fibrillation darmouth primary care COOP project [J]. Arch Intern Med, 1990, 150(1): 83-6.
  • 9Bungard TJ, Ghali WA, McAlister FA, et al. Physician perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation [J]. Can Med Assoc J, 2001,165(3): 301-2.
  • 10Christine D, Michel CS. Complications of warfarin therapy in older adults: a review [J]. lnt J Nurs Pract, 2010, 11(1): 1-3.

二级参考文献24

共引文献1

同被引文献62

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部